

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

Claims 1-43 (canceled)

Claim 44 (previously presented): An isolated antibody generated using a peptide consisting of SEQ ID NO: 1 or SEQ ID NO: 2 as an immunogen.

Claim 45 (previously presented): The antibody of claim 44, wherein the antibody is a monoclonal antibody.

Claim 46 (previously presented): The antibody of claim 44, wherein the antibody is a polyclonal antibody.

Claim 47 (previously presented): A composition comprising the antibody of claim 44 and a carrier.

Claim 48 (previously presented): A kit for detecting the activation of KDR/Flk-1 comprising the antibody of claim 44 and reagents for a detection assay.

Claim 49 (previously presented): The antibody of claim 44, wherein the antibody is a F(ab')₂, a Fab, or a single chain Fv.

Claim 50 (previously presented): A method of generating an antibody, comprising immunizing an animal with a peptide consisting of SEQ ID NO: 1 or SEQ ID NO: 2, and isolating the antibody from the animal.

Claim 51 (previously presented): The method of claim 50, wherein the animal is a mammal.

Claim 52 (previously presented): An isolated antibody generated by the method of claim 50.

Claim 53 (previously presented): An isolated antibody that binds to a peptide consisting of SEQ ID NO: 1 or SEQ ID NO: 2.

Claims 54-60 (canceled)

Claim 61 (previously presented): A method for detecting the presence of KDR/Flk-1 comprising mixing the antibody of claim 44 with a biological sample to detect the presence of KDR/Flk-1.

Claim 62 (previously presented): A method for measuring the amount of KDR/Flk-1 in a sample comprising mixing the antibody of claim 44 with a biological sample and measuring the amount of KDR/Flk-1 in the sample.

Claim 63 (previously presented): The method of claim 62, wherein measuring the amount of KDR/Flk-1 in the sample comprises performing an assay selected from the group consisting of a fluorimetric assay, a chromogenic assay, a radiolabelled assay, and a chemiluminescence assay.

Claims 64-66 (canceled)